objective To compare the efficacy of platinum and non-platinum-based regimens as first-line treatment for triple-negative breast cancer is advanced (TNBC) and analyze the relationship between their success and status of the BRCA genes.
method Retrospectively analyzed clinical data from 220 patients diagnosed with advanced pathological TNBC and treated in the Department of Breast Oncology, Peking University Cancer Hospital from 2013 to 2018 and evaluate the effectiveness of chemotherapy. A total of 114 patients had BRCA1 / 2 genes were tested by next generation sequencing (NGS) using peripheral blood, and we analyzed the correlation between efficacy and BRCA1 / 2 gene status.
result non-platinum-based chemotherapy (NPCT) was given to 129 and platinum-based chemotherapy (PBCT) to 91 study patients. The level of clinical benefit (CBR) and median progression-free survival (PFS) were not statistically different between groups NPCT and PBCT. Overall average life (OS) was 30.0 and 22.5 months for PBCT and NPCT groups, respectively [P = 0.090, hazard ratio (HR) = 0.703]. BRCA status assessed 114 patients, 14 of whom have a detrimental germline BRCA1 / 2 (gBRCA) mutation (seven in each group). In PBCT group, CBR was 85.7% and 35.1% for patients with and without mutations that destroy gBRCA, respectively (P = 0.039). Median PFS was 14.9 and 5.3 months and the median OS was 26.5 and 15.5 months for patients with and without mutations that destroy gBRCA, respectively (P = 0.001, P = 0.161, respectively). Patients in group PBCT have significantly greater levels of grade 3-4 anemia (5.5% vs. 0%) and thrombocytopenia (8.8% vs 0%), while the palmar-plantar erythrodysesthesia (12.4% vs 0% ) and peripheral neuropathy (8.6% vs. 1.1%) occurred more frequently in the group NPCT.
Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing.
conclusion platinum-based regimen was more effective in patients with mutations gBRCA damage, but there was no difference in patients without BRCA gene mutation, so that the non-platinum is an option in patients without BRCA gene mutation consider the toxicity and side effects. And we suggest that patients with advanced TNBC must have a BRCA gene test.
Description: Almorexant is an antagonist of Orexin 1 receptor (OX1R) and Orexin 2 receptor (OX2R) with Kd values of 1.3nM and 0.17nM, respectively [1].
Description: Almorexant is an antagonist of Orexin 1 receptor (OX1R) and Orexin 2 receptor (OX2R) with Kd values of 1.3nM and 0.17nM, respectively [1].
Description: Memantine hydrochloride is an antagonist of NMDA receptor with IC50 values of 0.93?M, 0.82?M and 0.47?M for NRIa/NR2A, NRIa/NR2B and NRIa/NR2D, respectively [1].
Description: Memantine hydrochloride is an antagonist of NMDA receptor with IC50 values of 0.93?M, 0.82?M and 0.47?M for NRIa/NR2A, NRIa/NR2B and NRIa/NR2D, respectively [1].
Description: Memantine hydrochloride is an antagonist of NMDA receptor with IC50 values of 0.93?M, 0.82?M and 0.47?M for NRIa/NR2A, NRIa/NR2B and NRIa/NR2D, respectively [1].
Description: Cyproheptadine hydrochloride is an antagonist of serotonin receptor [1]. Cyproheptadine is a serotonin and histamine antagonist as well as an antimuscarinic reagent.
Description: Cyproheptadine hydrochloride is an antagonist of serotonin receptor [1]. Cyproheptadine is a serotonin and histamine antagonist as well as an antimuscarinic reagent.
Description: Cyproheptadine hydrochloride is an antagonist of serotonin receptor [1]. Cyproheptadine is a serotonin and histamine antagonist as well as an antimuscarinic reagent.
Description: Moxonidine hydrochloride is a mixed agonist of ?2-adrenergic receptor (?2AR) and imidazoline-1 receptor(I1R) with Ki values of 4.2±3.2 nmol/L, 13.0±4.2 nmol/L.
Description: Moxonidine hydrochloride is a mixed agonist of ?2-adrenergic receptor (?2AR) and imidazoline-1 receptor(I1R) with Ki values of 4.2±3.2 nmol/L, 13.0±4.2 nmol/L.
Description: Moxonidine hydrochloride is a mixed agonist of ?2-adrenergic receptor (?2AR) and imidazoline-1 receptor(I1R) with Ki values of 4.2±3.2 nmol/L, 13.0±4.2 nmol/L.
Description: Bupropion hydrochloride is a dual effective inhibitor of norepinephrine and dopamine neurotransmitter with the IC50 values of 6.5 ± 0.6?M and 3.4 ± 0.4 ?M, respectively [1].
Description: Bupropion hydrochloride is a dual effective inhibitor of norepinephrine and dopamine neurotransmitter with the IC50 values of 6.5 ± 0.6?M and 3.4 ± 0.4 ?M, respectively [1].
Description: Bupropion hydrochloride is a dual effective inhibitor of norepinephrine and dopamine neurotransmitter with the IC50 values of 6.5 ± 0.6?M and 3.4 ± 0.4 ?M, respectively [1].
Description: Sotalol hydrochloride is a potent and non-selective antagonist of ?-adrenergic receptor. Sotalol is also an inhibitor of potassinm channels with the IC50 value of ~1.2mM in HEK cell lines [1].
Description: Sotalol hydrochloride is a potent and non-selective antagonist of ?-adrenergic receptor. Sotalol is also an inhibitor of potassinm channels with the IC50 value of ~1.2mM in HEK cell lines [1].
Description: Sotalol hydrochloride is a potent and non-selective antagonist of ?-adrenergic receptor. Sotalol is also an inhibitor of potassinm channels with the IC50 value of ~1.2mM in HEK cell lines [1].
Description: Sotalol hydrochloride is a potent and non-selective antagonist of ?-adrenergic receptor. Sotalol is also an inhibitor of potassinm channels with the IC50 value of ~1.2mM in HEK cell lines [1].
Description: Sotalol hydrochloride is a potent and non-selective antagonist of ?-adrenergic receptor. Sotalol is also an inhibitor of potassinm channels with the IC50 value of ~1.2mM in HEK cell lines [1].
Description: Vigabatrin Hcl(?-Vinyl-GABA; Sabril) is a structural analog of the inhibitory neurotransmitter ?-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.
Description: Vigabatrin Hcl(?-Vinyl-GABA; Sabril) is a structural analog of the inhibitory neurotransmitter ?-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.
Description: Vigabatrin Hcl(?-Vinyl-GABA; Sabril) is a structural analog of the inhibitory neurotransmitter ?-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.
Description: Ki: 8.39 nMSarpogrelate (MCI-9042) was shown to have the same affinity as ritanserin for 5-HT2A receptors, [1].The blockade of 5-HT2A receptors can inhibit thrombus formation suppresses platelet aggregation and inhibits vascular smooth muscle cell proliferation [2].
Description: Ki: 8.39 nMSarpogrelate (MCI-9042) was shown to have the same affinity as ritanserin for 5-HT2A receptors, [1].The blockade of 5-HT2A receptors can inhibit thrombus formation suppresses platelet aggregation and inhibits vascular smooth muscle cell proliferation [2].
Description: Ki: 8.39 nMSarpogrelate (MCI-9042) was shown to have the same affinity as ritanserin for 5-HT2A receptors, [1].The blockade of 5-HT2A receptors can inhibit thrombus formation suppresses platelet aggregation and inhibits vascular smooth muscle cell proliferation [2].
Description: Ki: 8.39 nMSarpogrelate (MCI-9042) was shown to have the same affinity as ritanserin for 5-HT2A receptors, [1].The blockade of 5-HT2A receptors can inhibit thrombus formation suppresses platelet aggregation and inhibits vascular smooth muscle cell proliferation [2].
Description: GW311616 hydrochloride is a potent, selective, intracellular, orally bioavailable and long duration inhibitor of human neutrophil elastase (HNE) with an IC50 value of 22nM [1].
Description: GW311616 hydrochloride is a potent, selective, intracellular, orally bioavailable and long duration inhibitor of human neutrophil elastase (HNE) with an IC50 value of 22nM [1].
Description: GW311616 hydrochloride is a potent, selective, intracellular, orally bioavailable and long duration inhibitor of human neutrophil elastase (HNE) with an IC50 value of 22nM [1].
Description: GW311616 hydrochloride is a potent, selective, intracellular, orally bioavailable and long duration inhibitor of human neutrophil elastase (HNE) with an IC50 value of 22nM [1].
Description: GW311616 hydrochloride is a potent, selective, intracellular, orally bioavailable and long duration inhibitor of human neutrophil elastase (HNE) with an IC50 value of 22nM [1].
Description: THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].THZ1 covalently modifies CDK7 by targeting C312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity.
Description: THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].THZ1 covalently modifies CDK7 by targeting C312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity.
Description: THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].THZ1 covalently modifies CDK7 by targeting C312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity.
Description: THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].THZ1 covalently modifies CDK7 by targeting C312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity.
Description: IC50: 19.1 nMJO 1784 is a selective ?1 receptor ligand.The CNS ? receptor ligands, as is known, modulates central neurotransmitter systems ( noradrenergic-, glutaminergic-, and dopaminergic-neurons was included).
Description: IC50: 19.1 nMJO 1784 is a selective ?1 receptor ligand.The CNS ? receptor ligands, as is known, modulates central neurotransmitter systems ( noradrenergic-, glutaminergic-, and dopaminergic-neurons was included).
Description: XL413 is a potent and selective Cdc7 inhibitor with an IC50 of 3.7 nM, >60-fold selectivity against CK2, >10-fold selectivity against PIM, and >300-fold selectivity against a panel of over 100 protein kinases. Phase 1
Description: XL413 is a potent and selective Cdc7 inhibitor with an IC50 of 3.7 nM, >60-fold selectivity against CK2, >10-fold selectivity against PIM, and >300-fold selectivity against a panel of over 100 protein kinases. Phase 1
Description: XL413 is a potent and selective Cdc7 inhibitor with an IC50 of 3.7 nM, >60-fold selectivity against CK2, >10-fold selectivity against PIM, and >300-fold selectivity against a panel of over 100 protein kinases. Phase 1
Description: XL413 is a potent and selective Cdc7 inhibitor with an IC50 of 3.7 nM, >60-fold selectivity against CK2, >10-fold selectivity against PIM, and >300-fold selectivity against a panel of over 100 protein kinases. Phase 1
)
)
)
-Igmesine hydrochloride)
